BRAINSTORM CELL THERAPEUTICS INC.
For the period ended Mar 31, 2026. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 31, 2026 · Filed Mar 31, 2026
Use the contents to explore the available documents and sections.
BCLI$1.14-7.3%Stored close · as of Jul 8, 2026
Contents
EX-99.1 · (Except share data)
(Except share data)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| U.S. $ in thousands | ||
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $29 | $187 |
| Other accounts receivable | 86 | 63 |
| Prepaid expenses and other current assets | 192 | 135 |
| Total current assets | $307 | $385 |
| Long-Term Assets: | ||
| Other long-term assets | $25 | $22 |
| Restricted Cash | 247 | 184 |
| Operating lease right of use asset (Note 4) | 208 | 807 |
| Property and Equipment, Net (Note 5) | 235 | 434 |
| Total Long-Term Assets | $715 | $1,447 |
| Total assets | $1,022 | $1,832 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current Liabilities: | ||
| Accounts payables | $7,067 | $6,080 |
| Accrued expenses | 396 | 619 |
| Short-term loans (Note 11) | 967 | 300 |
| Operating lease liability (Note 4) | 208 | 549 |
| Employees related liability | 2,369 | 1,430 |
| Total current liabilities | $11,007 | $8,978 |
| Long-Term Liabilities: | ||
| Operating lease liability (Note 4) | — | 171 |
| Warrants liability (Note 7) | — | 447 |
| Total long-term liabilities | $— | $618 |
| Total liabilities | $11,007 | $9,596 |
| Stockholders’ Deficit: | ||
| Stock capital: (Note 8) | 16 | 14 |
| Common Stock of $0.00005 par value - Authorized: 250,000,000 shares at December 31, 2025 and 100,000,000 shares at December 31, 2024 respectively; Issued and outstanding: 11,034,775 and 6,141,762 shares at December 31, 2025 and December 31, 2024 respectively | ||
| Additional paid-in-capital | 227,058 | 218,974 |
| Treasury stocks | (116) | (116) |
| Accumulated deficit | (236,943) | (226,636) |
| Total stockholders’ deficit | $(9,985) | $(7,764) |
| Total liabilities and stockholders’ deficit | $1,022 | $1,832 |
The accompanying notes are an integral part of the consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.